Analysis of Recorded Morbidity, Prevalence and Hospital Mortality of Patients with Symptomatic Multiple Myeloma in the Ryazan Region for 10 Years

Abstract

INTRODUCTION: Multiple myeloma (MM) is a disease whose substrate is plasma cells; it is characterized by the production of monoclonal immunoglobulin. Epidemiology of MM in Russia is insufficiently studied. Of interest is a study of dynamics of the main epidemiological parameters of multiple myeloma in the context of a poor epidemiological prognosis for oncological diseases in the Russian Federation and in the world in general.

AIM: To analyze the main epidemiological parameters of symptomatic MM in the Ryazan region for 10 years (2010–2019).

MATERIALS AND METHODS: A total of 343 medical records of patients with symptomatic MM were analyzed, of them 146 men (age median — 65 years), 197 women (age median — 64 years). The patients underwent inpatient treatment in the hematology and chemotherapy department of Ryazan Regional Clinical Hospital from 2010 to 2019. The epidemiological analysis consisted in evaluation of the parameters of the registered morbidity, prevalence and hospital mortality. The criterion for inclusion in the study was the existence of symptomatic MM in the patient. For statistical processing, Microsoft information and analytical system, Office package was used.

RESULTS: The highest amount of new cases of MM were identified in 2018 (4.19 per 100,000 population), the lowest — in 2012 (1.83 per 100,000 population). In the analyzed period, the number of cases of newly diagnosed MM per year increased by 30.3%. Most patients at the time of diagnosis were in the age group of 60−69 years. Morbidity with MM in the age group of 30−49 years was comparable in men and women, however, among the patients ≥ 50 years women predominated. Over 10 years, the index of MM prevalence in the Ryazan region increased 1.43 times: from 6.71 to 9.6 per 100,000 population, index of hospital mortality — from 1.4% to 3.3%.

CONCLUSION: The growth of the registered mortality and prevalence of MM in the Ryazan region in 2010−2019 was identified, which corresponds to the dynamics in other regions of the Russian Federation. Also, during the analyzed period, an increase in hospital mortality of patients with MM was observed in the region.

Keywords

multiple myeloma / epidemiology / registered morbidity / prevalence / hospital mortality / the Ryazan region

References

[1] Mnozhestvennaya miyeloma. Klinicheskiye rekomendatsii. Moscow; 2020. Available at: https://cr.minzdrav.gov.ru/schema/144_1. Accessed: 2022 September 14. (In Russ).

[2] Множественная миелома. Клинические рекомендации. М.; 2020. Доступно по: https://cr.minzdrav.gov.ru/schema/144_1. Ссылка активна на 14 сентября 2022.

[3] Skvortsova NV, Kovynev IB, Khalzov KV, et al. Comorbidity and Personalized Treatment of Multiple Myeloma in Real Clinical Practice. Clinical Oncohematology. 2020;13(3):322–34. (In Russ). doi: 10.21320/2500-2139-2020-13-3-322-334

[4] Скворцова Н.В., Ковынев И.Б., Хальзов К.В., и др. Коморбидность и персонализированная терапия множественной миеломы в реальной клинической практике // Клиническая онкогематология. 2020. T. 13, № 3. С. 322–334. doi: 10.21320/2500-2139-2020-13-3-322-334

[5] Davydkin IL, Shpigel’ AS, Mordvinova EV, еt al. Quality of life of patients with lymphoproliferative diseases. Astrakhan Medical Journal. 2021;16(2):6–18. (In Russ). doi: 10.17021/2021.16.2.6.18

[6] Давыдкин И.Л., Шпигель А.С., Мордвинова Е.В., и др. Качество жизни пациентов с лимфопролиферативными заболеваниями // Астраханский медицинский журнал. 2021. Т. 16, № 2. С. 6–18. doi: 10.17021/2021.16.2.6.18

[7] Luchinin AS, Semochkin SV, Minaeva NV, et al. Epidemiology of multiple myeloma according to the Kirov region population registers. Oncohematology. 2017;12(3):50–6. (In Russ). doi: 10.17650/1818 8346-2017-12-3-50-56

[8] Лучинин А.С., Семочкин С.В., Минаева Н.В., и др. Эпидемиология множественной миеломы по данным анализа популяционного регистра Кировской области // Онкогематология. 2017. T. 12, № 3. С. 50–56. doi: 10.17650/1818 8346-2017-12-3-50-56

[9] Ludwig H, Novis Durie S, Meckl A, et al. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. The Oncologist. 2020;25(9):e1406–13. doi: 10.1634/theoncologist.2020-0141

[10] Ludwig H., Novis Durie S., Meckl A., et al. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment // The Oncologist. 2020. Vol. 25, № 9. Р. 1406–1413. doi: 10.1634/theoncologist.2020-0141

[11] Skvortsova NV, Pospelova TI, Kovynev IB, et al. Epidemiology of Multiple Myeloma in Novosibirsk (Siberian Federal District). Clinical Oncohematology. 2019;12(1):86–94. (In Russ). doi: 10.21320/2500-2139-2019-12-1-86-94

[12] Скворцова Н.В., Поспелова Т.И., Ковынев И.Б., и др. Эпидемиология множественной миеломы в Новосибирске (Сибирский федеральный округ) // Клиническая онкогематология. 2019. T. 12, № 1. С. 86–94. doi: 10.21320/2500-2139-2019-12-1-86-94

[13] Vinogradova OY, Ptushkin VV, Chernikov MV, et al. Epidemiology of multiple myeloma in city Moscow. Therapeutic Archive. 2019;91(7):83–92. (In Russ). doi: 10.26442/00403660.2019.07.000305

[14] Виноградова О.Ю., Птушкин В.В., Черников М.В., и др. Эпидемиология множественной миеломы в городе Москва // Терапевтический архив. 2019. Т. 91, № 7. С. 83–92. doi: 10.26442/00403660.2019.07.000305

[15] Pogadaeva MS, Setko IA, Yarnyh AV. Epidemiology of Multiple Myeloma of the Orenburg region. Abstracts Nationwide scientific forum of students with international participation «Student science — 2020. Forcipe. 2020;3(S1):161–2. (In Russ).

[16] Погадаева М.С., Сетко И.А., Ярных А.В. Эпидемиология множественной миеломы в Оренбургской области. Материалы всероссийского научного форума студентов с международным участием «Студенческая наука — 2020» // Forcipe. 2020. Т. 3, № S1. С. 161–162.

[17] Zvereva ON. Mnozhestvennaya miyeloma u naseleniya Arkhangel’ska. Gematologiya i Transfuziologiya. 2012;57(3, Suppl):110–1. (In Russ).

[18] Зверева О.Н. Множественная миелома у населения Архангельска // Гематология и трансфузиология. 2012. Т. 57, № 3 (Прил.). С. 110–111.

[19] Pivnik AV, Vorob’yeva TV, Volodicheva EM. Analiz zabolevayemosti mnozhestvennoy miyelomoy v Tul’skoy oblasti. Problemy Gematologii i Perelivaniya Krovi. 2000;(4):31–4. (In Russ).

[20] Пивник А.В., Воробьева Т.В., Володичева Е.М. Анализ заболеваемости множественной миеломой в Тульской области // Проблемы гематологии и переливания крови. 2000. № 4. C. 31–34.

[21] Bolotin SG, Zenina MS, Pristupa AS, et al. Clinical and epidemiological characteristics of multiple myeloma in the Ryazan region. Nauka Molodykh (Eruditio Juvenium). 2020;8(4):541–8. (In Russ). doi: 10.23888/HMJ202084541-548

[22] Болотин С.Г., Зенина М.С., Приступа А.С., и др. Клинико-эпидемиологическая характеристика множественной миеломы в Рязанской области // Наука молодых (Eruditio Juvenium). 2020. Т. 8, № 4. С. 541–548. doi: 10.23888/HMJ202084541-548

[23] Butukhanova IS, Zhalsanova EB, Alekseeva AN, et al. The analysis of the multiple myeloma morbidity in Buryatia republic. Modern Problems of Science and Education. 2016;(4). Available at: https://science-education.ru/ru/article/view?id=24818. Accessed: 2022 September 14. (In Russ).

[24] Бутуханова И.С., Жалсанова Э.Б., Алексеева А.Н., и др. Анализ заболеваемости множественной миеломой в республике Бурятия// Современные проблемы науки и образования. 2016. № 4. Доступно по: https://science-education.ru/ru/article/view?id=24818. Ссылка активна на 14 сентября 2022.

[25] Population and Census Data. Available at: https://eng.rosstat.gov.ru/folder/11654. Accessed: 2022 September 14. (In Russ).

[26] Население. Доступно по: https://ryazan.gks.ru/folder/30448. Ссылка активна на 14 сентября 2022.

RIGHTS & PERMISSIONS

Eco-Vector